Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

PARP Inhibitors Are Changing Diagnostic and Therapeutic Landscape in Ovarian Cancer

August 16th 2017

PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have broadened in recent months.

Dr. Leath Discusses Surgical Cytoreduction in Ovarian Cancer

August 16th 2017

Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.

Expert Discusses Promise of Mirvetuximab Soravtansine in Ovarian Cancer

August 14th 2017

Kathleen Moore, MD, discusses the potential of mirvetuximab soravtansine in patients with epithelial ovarian cancer.

Expert Weighs in on PARP Inhibitor Advances in Ovarian Cancer

August 8th 2017

Douglas Levine, MD, provides his insight on some of the recent data with PARP inhibitors in ovarian cancer, as well as his predictions for the field in the next several years.

Comprehensive Genomic Profiling May Identify Select Subsets in Ovarian Cancer

August 7th 2017

Julia A. Elvin, MD, PhD, discusses genomic research in ovarian cancer and how it could potentially impact treatment decisions for patients.

Dr. du Bois on Study of Secondary Cytoreductive Surgery in Ovarian Cancer

August 2nd 2017

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses his study of secondary cytoreductive surgery in ovarian cancer.

Maintenance Olaparib Data Published as FDA Weighs Approval

August 1st 2017

The FDA granted a priority review in March to a new drug application for maintenance olaparib, and is scheduled to make its final decision on the PARP inhibitor before the end of the year.

AstraZeneca: Pioneers in Ovarian Cancer

July 18th 2017

Since the approval of LYNPARZA, over 3,000 US women with germline BRCA-mutated advanced ovarian cancer have been treated with this important medicine.

Emerging Novel Agents for Ovarian Cancer

July 14th 2017

Potential for Immunotherapy in Ovarian Cancer

July 14th 2017

Sequencing for Treatment for Recurrent Ovarian Cancer

July 14th 2017

Difference Among PARP Inhibitors for Ovarian Cancer

July 14th 2017

Niraparib Maintenance for Recurrent Ovarian Cancer

July 14th 2017

Rucaparib for Recurrent Ovarian Cancer

July 14th 2017

Olaparib Maintenance for Recurrent Ovarian Cancer

July 14th 2017

When to Add Bevacizumab for Recurrent Ovarian Cancer

July 14th 2017

Secondary Debulking in Recurrent Ovarian Cancer

July 14th 2017

Key Considerations for Treating Recurrent Ovarian Cancer

July 14th 2017

Upfront Antiangiogenic Therapy in Advanced Ovarian Cancer

July 14th 2017

Optimizing Chemotherapy for Advanced Ovarian Cancer

July 14th 2017

x